COSMO BIO, Jan-Mar (1Q) Ordinary Profit Decreases by 2%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri May 9, 2025 3:30 pm JST Earnings

3386 COSMO BIO COMPANY, LIMITED 【J-GAAP】

Earnings Report

COSMO BIO COMPANY, LIMITED <3386> [TSE Std] announced its financial results after the market closed on May 9th (15:30). The consolidated ordinary profit for the first quarter of the fiscal year ending December 2025 (January to March) was 293 million yen, a 2.0% decrease compared to the same period last year. The progress rate toward the plan for the six months ending June (1H) of 360 million yen was 81.4%, almost the same as the five-year average of 80.0%.

In the most recent three-month period, from January to March (1Q), the operating profit margin decreased from 10.4% in the same period last year to 8.8%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Mar, 2023	2,828	400	416	264	45.5	75.4	May 10, 2023	J-GAAP
Jan - Mar, 2024	2,943	305	299	230	39.6	88.7	May 9, 2024	J-GAAP
Jan - Mar, 2025	3,093	273	293	212	37.2	81.4	May 9, 2025	J-GAAP
YoY	+5.1%	-10.5%	-2.0%	-7.8%	-5.9%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2024	5,129	322	337	258	44.2	14	Aug 5, 2024	J-GAAP
Jan - Jun, 2025 Guidance	5,500	290	360	280	49.1	25	Feb 14, 2025	J-GAAP
YoY	+7.2%	-9.9%	+6.8%	+8.5%	+11.2%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	9,340	519	653	442	76.0	30	Feb 14, 2024	J-GAAP
Dec, 2024	10,037	318	364	262	45.1	50	Feb 14, 2025	J-GAAP
Dec, 2025 Guidance	10,700	490	580	430	75.8	50	Feb 14, 2025	J-GAAP
YoY	+6.6%	+54.1%	+59.3%	+64.1%	+68.2%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	2,943	305	299	230	39.6	10.4	May 9, 2024	J-GAAP
Apr - Jun, 2024	2,186	17	38	28	4.8	0.8	Aug 5, 2024	J-GAAP
Jul - Sep, 2024	2,280	47	47	33	5.7	2.1	Nov 7, 2024	J-GAAP
Oct - Dec, 2024	2,628	-51	-20	-29	-5.0	-1.9	Feb 14, 2025	J-GAAP
Jan - Mar, 2025	3,093	273	293	212	37.2	8.8	May 9, 2025	J-GAAP
YoY	+5.1%	-10.5%	-2.0%	-7.8%	-5.9%